.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Queensland Health
Chubb
Express Scripts
Fuji
Citi
Deloitte
US Army
Cerilliant
Mallinckrodt

Generated: July 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,076,361

« Back to Dashboard

Details for Patent: 8,076,361

Title:Form of S-omeprazole
Abstract: The present invention relates to a novel form of the (-)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2 -pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
Inventor(s): Cotton; Hanna (Sodertalje, SE), Kronstrom; Anders (Sodertalje, SE), Mattson; Anders (Sodertalje, SE), Moller; Eva (Sodertalje, SE)
Assignee: AstraZeneca AB (Sodertalje, SE)
Filing Date:May 21, 2010
Application Number:12/784,881
Claims:1. A method of treating Helicobacter infections comprising the administration of an effective amount of a pharmaceutical composition comprising the magnesium salt of S-omeprazole trihydrate and an antibacterial compound to a patient in need thereof.

2. The method according to claim 1, wherein the magnesium salt of S-omeprazole trihydrate is represented by FIG. 1.

3. The method according to claim 1, wherein the magnesium salt of S-omeprazole trihydrate is characterized by the following peaks in its X-ray diffractogram: TABLE-US-00007 d-value/.ANG. Relative Intensity 2.67 M 2.79 M 3.27 M 3.52 S 3.82 S 3.96 Vs 4.14 M 5.2 M 5.6 M 6.7 Vs 6.9 S 8.3 W 16.6 Vs.

4. The method according to claim 1, wherein the magnesium salt of S-omeprazole trihydrate is in a highly crystalline form.

5. The method according to claim 1, wherein the magnesium salt of S-omeprazole trihydrate is in a stable form.

6. The method according to claim 1, wherein the pharmaceutical composition is in unit dose form suitable for peroral or parenteral administration.

7. The method according to claim 1, wherein the total daily dose of the magnesium salt of S-omeprazole trihydrate is from 10 mg to 80 mg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Baxter
Fuji
Deloitte
US Department of Justice
Medtronic
Dow
Chinese Patent Office
Julphar
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot